CR10831A - INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA - Google Patents
INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASAInfo
- Publication number
- CR10831A CR10831A CR10831A CR10831A CR10831A CR 10831 A CR10831 A CR 10831A CR 10831 A CR10831 A CR 10831A CR 10831 A CR10831 A CR 10831A CR 10831 A CR10831 A CR 10831A
- Authority
- CR
- Costa Rica
- Prior art keywords
- ketona
- carboxilasa
- espiro
- acetil
- coa
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86177906P | 2006-11-29 | 2006-11-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR10831A true CR10831A (es) | 2009-06-18 |
Family
ID=39126209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR10831A CR10831A (es) | 2006-11-29 | 2009-05-28 | INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20090270435A1 (es) |
| EP (1) | EP2097420B1 (es) |
| JP (1) | JP2010511035A (es) |
| KR (1) | KR20090083956A (es) |
| CN (1) | CN101541809A (es) |
| AP (1) | AP2009004880A0 (es) |
| AT (1) | ATE552262T1 (es) |
| AU (1) | AU2007326950B2 (es) |
| BR (1) | BRPI0721053A2 (es) |
| CA (1) | CA2670422C (es) |
| CO (1) | CO6180424A2 (es) |
| CR (1) | CR10831A (es) |
| EA (1) | EA200900613A1 (es) |
| EC (1) | ECSP099371A (es) |
| IL (1) | IL198779A0 (es) |
| MA (1) | MA30932B1 (es) |
| MX (1) | MX2009005604A (es) |
| NO (1) | NO20091889L (es) |
| RS (1) | RS20090249A (es) |
| SV (1) | SV2009003281A (es) |
| TN (1) | TN2009000204A1 (es) |
| WO (1) | WO2008065508A1 (es) |
| ZA (1) | ZA200903268B (es) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8138197B2 (en) | 2007-01-12 | 2012-03-20 | Msd K.K. | Spirochromanon derivatives |
| PE20081559A1 (es) * | 2007-01-12 | 2008-11-20 | Merck & Co Inc | DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA |
| CN100550853C (zh) * | 2007-01-25 | 2009-10-14 | 华为技术有限公司 | 一种基于输出队列的流控实现方法及装置 |
| DE102007028521A1 (de) * | 2007-06-21 | 2008-12-24 | Merck Patent Gmbh | Indazolamidderivate |
| CA2724603A1 (en) * | 2008-05-28 | 2009-12-03 | Pfizer Inc. | Pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| WO2009144554A1 (en) * | 2008-05-28 | 2009-12-03 | Pfizer, Inc. | Pyrazolospiroketone acetyl-c0a carboxylase inhibitors |
| US8524730B2 (en) | 2008-07-04 | 2013-09-03 | Msd K.K. | Spirochromanone carboxylic acids |
| WO2010008521A1 (en) | 2008-07-14 | 2010-01-21 | Cropsolution, Inc. | Modulators of acetyl-coenzyme a carboxylase and methods of use thereof |
| DE102008038222A1 (de) | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | Indazol-5-carbonsäurehydrazid-derivate |
| EP2184276A1 (en) | 2008-11-07 | 2010-05-12 | Universite Paul Cezanne Aix-Marseille Iii | Process to prepare new substituted 1H-Benzo(d) imidazol-2(3h)-Ones, New intermediates and their use as bace 1 inhibitors |
| PT2499139E (pt) | 2009-11-10 | 2014-02-10 | Pfizer | Inibidores de n1-pirazolospirocetona acetil-coa carboxilase |
| JP2013510191A (ja) * | 2009-11-10 | 2013-03-21 | ファイザー・インク | Ｎ−２ピラゾロスピロケトンアセチル−ＣｏＡカルボキシラーゼ阻害薬 |
| PL2547679T3 (pl) | 2010-03-19 | 2016-02-29 | Pfizer | Pochodne 2,3-dihydro-1H-inden-1-ylo-2,7-diazaspiro[3.5]nonanu i ich zastosowanie jako antagonistów lub odwrotnych agonistów receptora greliny |
| CA2812526A1 (en) | 2010-05-06 | 2011-11-10 | Vertex Pharmaceuticals Incorporated | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels |
| US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| HRP20161178T1 (hr) | 2010-09-30 | 2016-11-04 | Pfizer Inc. | N1-PIRAZOLOSPIROKETONSKI INHIBITORI ACETIL-CoA-KARBOKSILAZE |
| HUE025078T2 (en) | 2010-10-29 | 2016-01-28 | Pfizer | N1 / N2-lactam-acetyl-CoA carboxylase inhibitors |
| BR112013019211A2 (pt) | 2011-02-02 | 2021-07-06 | Vertex Pharma | amidas de piperidina espirocíclicas de pirrolopirazina como moduladores de canais de íon |
| CN103443105A (zh) * | 2011-02-18 | 2013-12-11 | 沃泰克斯药物股份有限公司 | 作为离子通道调节剂的苯并二氢吡喃-螺环哌啶酰胺 |
| US8828996B2 (en) | 2011-03-14 | 2014-09-09 | Vertex Pharmaceuticals Incorporated | Morpholine-spirocyclic piperidine amides as modulators of ion channels |
| PE20141187A1 (es) | 2011-04-22 | 2014-09-18 | Pfizer | Inhibidores sustituidos de aeitl-coa carboxilasa |
| JP5955954B2 (ja) | 2011-07-08 | 2016-07-20 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | ２−アミノ−５−シアノ−ｎ，３−ジメチルベンズアミドを製造する方法 |
| CA2841757A1 (en) | 2011-07-15 | 2013-01-24 | Etzer Darout | Gpr 119 modulators |
| RU2013157388A (ru) | 2011-07-22 | 2015-08-27 | Пфайзер Инк. | Хинолинильные модуляторы глюкагонового рецептора |
| SI2746265T1 (sl) | 2011-08-18 | 2016-03-31 | Nippon Shinyaku Co., Ltd. | Heterociklični derivat kot zaviralec mikrosomske prostaglandin-e sintaze (mpges) |
| JP6043355B2 (ja) | 2011-08-31 | 2016-12-14 | ファイザー・インク | ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物 |
| GEP201706656B (en) | 2011-11-11 | 2017-04-25 | Pfizer | 2-thiopyrimidinones |
| SG11201405477XA (en) | 2012-04-06 | 2014-11-27 | Pfizer | Diacylglycerol acyltransferase 2 inhibitors |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| ES2585262T3 (es) | 2012-05-04 | 2016-10-04 | Pfizer Inc | Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2 |
| CA2882389A1 (en) | 2012-09-20 | 2014-03-27 | Pfizer Inc. | Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| WO2014091352A1 (en) | 2012-12-11 | 2014-06-19 | Pfizer Inc. | Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1 |
| CA2893333C (en) | 2012-12-19 | 2017-10-24 | Pfizer Inc. | Carbocyclic-and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| WO2014125394A1 (en) | 2013-02-13 | 2014-08-21 | Pfizer Inc. | HETEROARYL-SUBSTITUTED HEXAHYDROPYRANO [3,4-d][1,3] THIAZIN-2-AMINE COMPOUNDS |
| US9233981B1 (en) | 2013-02-15 | 2016-01-12 | Pfizer Inc. | Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| JP6348582B2 (ja) | 2013-10-09 | 2018-06-27 | ファイザー・インク | プロスタグランジンｅｐ３受容体の拮抗薬 |
| EP3119757B1 (en) | 2014-03-17 | 2018-05-16 | Pfizer Inc | Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders |
| WO2015150995A1 (en) | 2014-04-04 | 2015-10-08 | Pfizer Inc. | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors |
| CR20160455A (es) | 2014-04-10 | 2016-12-16 | Pfizer | 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILA |
| WO2016092413A1 (en) | 2014-12-10 | 2016-06-16 | Pfizer Inc. | Indole and indazole compounds that activate ampk |
| EP3237401B1 (en) | 2014-12-22 | 2019-03-06 | Pfizer Inc | Antagonists of prostaglandin ep3 receptor |
| MA42035A (fr) | 2015-05-05 | 2018-03-14 | Pfizer | 2-thiopyrimidinones |
| US10308615B2 (en) | 2015-05-29 | 2019-06-04 | Pfizer Inc. | Heterocyclic compounds as inhibitors of Vanin-1 enzyme |
| ES2832893T3 (es) | 2015-06-17 | 2021-06-11 | Pfizer | Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa |
| WO2016203335A1 (en) | 2015-06-18 | 2016-12-22 | Pfizer Inc. | Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors |
| AU2016305590A1 (en) | 2015-08-13 | 2018-02-15 | Pfizer Inc. | Bicyclic-fused heteroaryl or aryl compounds |
| RS61719B1 (sr) | 2015-08-27 | 2021-05-31 | Pfizer | Biciklična fuzionisana hetaroaril ili aril jedinjenja kao modulatori irak4 |
| WO2017037567A1 (en) | 2015-09-03 | 2017-03-09 | Pfizer Inc. | Regulators of frataxin |
| EP3353174A1 (en) | 2015-09-24 | 2018-08-01 | Pfizer Inc | N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl]amides useful as bace inhibitors |
| WO2017051276A1 (en) | 2015-09-24 | 2017-03-30 | Pfizer Inc. | N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides |
| JP2018531924A (ja) | 2015-09-24 | 2018-11-01 | ファイザー・インク | テトラヒドロピラノ［３，４−ｄ］［１，３］オキサジン誘導体、およびｂａｃｅ阻害剤としてのその使用 |
| JP6503515B2 (ja) | 2015-12-29 | 2019-04-17 | ファイザー・インク | ケトヘキソキナーゼ阻害薬としての置換３−アザビシクロ［３．１．０］ヘキサン |
| MX2019000536A (es) | 2016-07-14 | 2019-04-01 | Pfizer | Nuevas pirimidinas carboxamidas como inhibidores de enzima vanina-1. |
| AR109179A1 (es) | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
| WO2019133445A1 (en) | 2017-12-28 | 2019-07-04 | Inception Ibd, Inc. | Aminothiazoles as inhibitors of vanin-1 |
| CN108658938B (zh) * | 2018-06-15 | 2021-03-23 | 上海现代制药股份有限公司 | 一种甲磺酸达比加群酯工艺杂质的合成方法 |
| CN108774242B (zh) * | 2018-08-22 | 2020-10-27 | 牡丹江医学院 | 一种防治冠心病的药物及其制备方法 |
| BR112021003039A2 (pt) | 2018-08-31 | 2021-05-18 | Pfizer Inc. | combinações para o tratamento de nash/nafld e doenças relacionadas |
| CN109400618B (zh) * | 2018-11-09 | 2021-08-10 | 中国药科大学 | 一种色满衍生物及其制备方法和应用 |
| WO2020102575A1 (en) | 2018-11-16 | 2020-05-22 | Inception Ibd, Inc. | Heterocyclic aminothiazoles and uses thereof |
| CN109809992A (zh) * | 2019-02-16 | 2019-05-28 | 安徽华胜医药科技有限公司 | 一种2-（2-氟-3-甲氧基苯基）-2-羟基乙酸乙酯的合成方法 |
| US12611401B2 (en) | 2019-05-20 | 2026-04-28 | Pfizer Inc. | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases |
| CN110128347A (zh) * | 2019-06-17 | 2019-08-16 | 韶远科技（上海)有限公司 | 一种1-甲基-1h-吲唑-6-甲酸的合成方法 |
| GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| PE20231066A1 (es) | 2020-02-07 | 2023-07-17 | Gasherbrum Bio Inc | Agonistas heterociclicos de glp-1 |
| EP4143183B1 (en) | 2020-04-29 | 2025-10-22 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2022095971A1 (zh) * | 2020-11-06 | 2022-05-12 | 上海医药集团股份有限公司 | 一种螺杂环类化合物、其制备方法及应用 |
| JP2025509281A (ja) | 2022-03-09 | 2025-04-11 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環式ｇｌｐ－１アゴニスト |
| EP4508047A1 (en) | 2022-04-14 | 2025-02-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2024118524A1 (en) | 2022-11-28 | 2024-06-06 | Cerevel Therapeutics, Llc | Azaindole compounds and their use as phosphodiesterase inhibitors |
| KR20250157491A (ko) | 2022-12-15 | 2025-11-04 | 가셔브룸 바이오, 인크. | Glp-1 효능제 활성을 갖는 화합물의 염 및 고체 형태 |
| WO2025036472A1 (en) * | 2023-08-16 | 2025-02-20 | Pharmaengine, Inc. | Spirocyclic mta-cooperative prmts inhibitor |
| WO2025133948A1 (en) * | 2023-12-21 | 2025-06-26 | Pfizer Inc. | Acetyl coa-carboxylase (acc) inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL96507A0 (en) * | 1989-12-08 | 1991-08-16 | Merck & Co Inc | Nitrogen-containing spirocycles and pharmaceutical compositions containing them |
| JP2001516330A (ja) * | 1995-06-06 | 2001-09-25 | メルク エンド カンパニー インコーポレーテッド | アルファ１ａアドレナリンレセプターアンタゴニスト |
| WO2002020509A2 (de) * | 2000-09-06 | 2002-03-14 | Bayer Aktiengesellschaft | Arzneimittel gegen virale erkrankungen |
| JPWO2004092179A1 (ja) * | 2003-04-14 | 2006-07-06 | 日本曹達株式会社 | スピロ誘導体、製造法および抗酸化薬 |
| JP2005119987A (ja) * | 2003-10-15 | 2005-05-12 | Ajinomoto Co Inc | アシルスルホンアミド誘導体 |
| US8138342B2 (en) * | 2004-10-12 | 2012-03-20 | High Point Pharmacueticals, LLC | 11β-hydroxysteroid dehydrogenase type 1 active spiro compounds |
| US20090215742A1 (en) * | 2005-05-03 | 2009-08-27 | Pfizer, Inc. | Amide resorcinol compounds |
| KR20080036041A (ko) * | 2005-07-19 | 2008-04-24 | 머크 앤드 캄파니 인코포레이티드 | 아세틸 조효소 카복실라제(ａｃｃ) 억제제로서의스피로크로마논 유도체 |
-
2007
- 2007-11-16 EP EP07825738A patent/EP2097420B1/en active Active
- 2007-11-16 AT AT07825738T patent/ATE552262T1/de active
- 2007-11-16 JP JP2009538803A patent/JP2010511035A/ja active Pending
- 2007-11-16 CA CA2670422A patent/CA2670422C/en not_active Expired - Fee Related
- 2007-11-16 MX MX2009005604A patent/MX2009005604A/es not_active Application Discontinuation
- 2007-11-16 US US12/514,596 patent/US20090270435A1/en not_active Abandoned
- 2007-11-16 AU AU2007326950A patent/AU2007326950B2/en not_active Expired - Fee Related
- 2007-11-16 KR KR1020097013481A patent/KR20090083956A/ko not_active Ceased
- 2007-11-16 EA EA200900613A patent/EA200900613A1/ru unknown
- 2007-11-16 AP AP2009004880A patent/AP2009004880A0/xx unknown
- 2007-11-16 BR BRPI0721053-1A patent/BRPI0721053A2/pt not_active IP Right Cessation
- 2007-11-16 WO PCT/IB2007/003639 patent/WO2008065508A1/en not_active Ceased
- 2007-11-16 CN CNA2007800442537A patent/CN101541809A/zh active Pending
- 2007-11-16 RS RSP-2009/0249A patent/RS20090249A/sr unknown
-
2009
- 2009-05-12 ZA ZA200903268A patent/ZA200903268B/xx unknown
- 2009-05-14 NO NO20091889A patent/NO20091889L/no not_active Application Discontinuation
- 2009-05-14 IL IL198779A patent/IL198779A0/en unknown
- 2009-05-22 TN TNP2009000204A patent/TN2009000204A1/fr unknown
- 2009-05-28 CO CO09054954A patent/CO6180424A2/es not_active Application Discontinuation
- 2009-05-28 CR CR10831A patent/CR10831A/es not_active Application Discontinuation
- 2009-05-29 EC EC2009009371A patent/ECSP099371A/es unknown
- 2009-05-29 SV SV2009003281A patent/SV2009003281A/es not_active Application Discontinuation
- 2009-05-29 MA MA31936A patent/MA30932B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2097420A1 (en) | 2009-09-09 |
| MX2009005604A (es) | 2009-06-08 |
| AU2007326950A1 (en) | 2008-06-05 |
| BRPI0721053A2 (pt) | 2014-07-29 |
| CA2670422A1 (en) | 2008-06-05 |
| ATE552262T1 (de) | 2012-04-15 |
| MA30932B1 (fr) | 2009-11-02 |
| AP2009004880A0 (en) | 2009-06-30 |
| NO20091889L (no) | 2009-06-17 |
| WO2008065508A1 (en) | 2008-06-05 |
| SV2009003281A (es) | 2010-08-17 |
| CA2670422C (en) | 2011-09-06 |
| US20090270435A1 (en) | 2009-10-29 |
| TN2009000204A1 (fr) | 2010-10-18 |
| ZA200903268B (en) | 2010-07-28 |
| AU2007326950B2 (en) | 2010-10-14 |
| KR20090083956A (ko) | 2009-08-04 |
| RS20090249A (sr) | 2010-06-30 |
| EP2097420B1 (en) | 2012-04-04 |
| CO6180424A2 (es) | 2010-07-19 |
| JP2010511035A (ja) | 2010-04-08 |
| EA200900613A1 (ru) | 2009-10-30 |
| IL198779A0 (en) | 2010-02-17 |
| CN101541809A (zh) | 2009-09-23 |
| ECSP099371A (es) | 2009-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2041138T3 (da) | Pyrroltriazinkinase-inhibitorer | |
| DK2024375T3 (da) | Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere | |
| CY2017016I1 (el) | Αναστολεις πρωτεασωματος | |
| BRPI0719204A2 (pt) | Inibidores de hdac | |
| EP2051707A4 (en) | Plasma kallikrein INHIBITORS | |
| CR10841A (es) | Imidazotriazinas imidazopirimidinas inhibidores de cinasa | |
| DE602006004717D1 (de) | Kapselperforationsmodul | |
| DE602007002544D1 (de) | Nuancierungsmittel | |
| DE602007008423D1 (de) | Flüssigkeitshärtung | |
| DE602007003893D1 (de) | Kippambossanordnung | |
| AT504580A3 (de) | Scan-einrichtung | |
| DE602007006947D1 (de) | Pyridopyrimidinonderivate | |
| DE602007000258D1 (de) | Kassetteneinspannmechanismus | |
| DE602007001280D1 (de) | Getränkeextraktor | |
| DE502007001629D1 (de) | Rfahren | |
| DE602006020192D1 (de) | Riemenscheibenanorndung | |
| ATE546437T1 (de) | Aminomethyl-4-imidazole | |
| DE502007000218D1 (de) | nsetzungen | |
| DE602007000501D1 (de) | Breitbandrichtkoppler | |
| DE602007001098D1 (de) | Spindelmäheinheit | |
| DE502007002453D1 (de) | Kunstoffverdichtergehäuse | |
| DE602007004080D1 (de) | Tintenstrahlaufnehmer | |
| DE602007007460D1 (de) | Sehkrafttestsystem | |
| DK2066662T3 (da) | Serinhydrolaseinhibitorer | |
| DE602007000333D1 (de) | Napfbefestigungsvorrichtung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal (granting procedure) |